Pulmonary arterial hypertension (PAH) is a disabling chronic disorder of the pulmonary
vasculature, which is characterized by increased pulmonary artery pressure as a result of …

Objectives HIV‐related pulmonary arterial hypertension (PAH) is a rare entity but is
associated with significant morbidity and mortality. The literature describing the outcomes of …

Pulmonary hypertension (PH) affects> 25 million individuals worldwide and causes
premature disability and death for many. The diagnosis and treatment of PH have advanced …

Pulmonary arterial hypertension is defined as a mean pulmonary arterial pressure greater
than 25 mm Hg at rest or 30 mm Hg during physical activity. Pulmonary arterial hypertension …

Background We aimed to investigate the extent of pharmacokinetic drug interactions
between bosentan and a fixed combination of lopinavir/ritonavir. Methods This was a three …

The introduction of highly active antiretroviral therapy (HAART) has generated a contrast in
the cardiac manifestations of acquired immunodeficiency syndrome. In developed countries …

Importance to the field: Pulmonary arterial hypertension (PAH) is a morbid condition with
high mortality if left untreated. Bosentan is an effective treatment option for group 1 …

The first descriptions of pulmonary arterial hypertension (PAH) have fascinated clinicians
and scientists since these brief initial descriptions. Despite significant advances in the …

Die 2009 veröffentlichen Europäischen Leitlinien zur Diagnostik und Therapie der
pulmonalen Hypertonie sind nunmehr auch in Deutschland gültig. Die Leitlinien befassen …

Pulmonary hypertension is characterized by an increase in mean pulmonary arterial
pressure and right ventricular overload. Endothelin-1 (ET-1) is a potent vasoconstrictor with …